United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $523.14, for a total value of $4,342,062.00. Following the sale, the executive vice president owned 45,172 shares in the company, valued at $23,631,280.08. The trade was a 15.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

United Therapeutics Stock Down 1.5%

Shares of UTHR opened at $513.12 on Friday. The business has a fifty day moving average of $533.08 and a 200 day moving average of $537.36. The company has a market cap of $22.01 billion, a PE ratio of 18.36, a P/E/G ratio of 1.76 and a beta of 0.59. United Therapeutics Corporation has a 52-week low of $302.19 and a 52-week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business’s revenue was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $6.41 earnings per share. As a group, research analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Institutional Trading of United Therapeutics

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in United Therapeutics in the second quarter valued at approximately $2,868,735,000. Wellington Management Group LLP increased its holdings in shares of United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares in the last quarter. Jupiter Topco LLC purchased a new position in shares of United Therapeutics during the 2nd quarter valued at approximately $450,140,000. Norges Bank purchased a new stake in United Therapeutics during the fourth quarter worth $293,418,000. Finally, Avoro Capital Advisors LLC grew its position in United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after buying an additional 383,838 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. JPMorgan Chase & Co. lifted their price target on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Morgan Stanley set a $515.00 price target on United Therapeutics in a research note on Thursday, August 6th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Finally, Weiss Ratings upgraded United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $646.00.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.